Leidos Holdings, Inc LDOS reported second-quarter fiscal 2024 revenue growth of 8% year-over-year to $4.13 billion, beating the analyst consensus estimate of $4.06 billion, driven by demand across all customer segments, especially for managed health services.
The defense, aviation, information technology, and biomedical research company’s adjusted EPS was $2.63, up 46% year over year, beating the analyst consensus estimate of $2.27.
Adjusted net income was $358 million for the quarter, up 43.8% year-over-year.
Adjusted EBITDA was $559 million, up 33% year over year. The margin of 13.5% increased from 10.9% a year ago.
Net bookings totaled $4.0 billion for the quarter, representing a book-to-bill ratio of 1.0. As a result, the backlog at the end of the year was $36.5 billion, of which $8.0 billion was funded.
Leidos held $823 million in cash and equivalents as of June 28, 2024.
CEO Thomas Bell commented, “Our collaborative innovation strategy and capabilities-based organization position us well to deliver on our commitments for the remainder of 2024 and beyond.”
Outlook: Leidos expects fiscal 2024 revenue of $16.1 billion-$16.4 billion (prior $16.0 billion – $16.4 billion). The analyst consensus stands at $16.25 billion.
The company expects its fiscal 2024 adjusted EPS of $8.60 – $9.00 (prior $8.40 – $8.80) versus the $8.82 consensus.
Leidos Holdings stock gained 64% in the last 12 months.
Price Action: LDOS shares are trading lower by 3.29% at $147.93 at the last check on Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.